Physician profile
Rafiullah Khan
NPI 1336304294
$11,461.51
in general payments reported to CMS, 2019-2025
23 companies · $2,114 in 2025
The $2,114 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $241 · 2022: $365 · 2023: $3,343 · 2024: $5,061 · 2025: $2,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,015 · Food and Beverage: $1,777 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,015.00 |
| Food and Beverage | $1,777.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,725.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,225.92 | 2022-2025 | Calquence |
| Beigene USA, INC. | $2,958.19 | 2022-2023 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $1,725.00 | 2024 | Tazverik |
| Incyte Corporation | $1,650.00 | 2025 | |
| Genzyme Corporation | $333.92 | 2020-2025 | |
| Celgene Corporation | $282.23 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $254.17 | 2022-2024 | Reblozyl |
| Pharmacosmos Therapeutics INC. | $176.82 | 2024 | Monoferric |
| Beone Medicines USA, INC. | $126.50 | 2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $122.04 | 2019 | |
| Adaptive Biotechnologies Corporation | $96.22 | 2025 | Clonoseq |
| Astellas Pharma US INC | $95.00 | 2019 | |
| Adc Therapeutics America, INC. | $91.59 | 2023 | |
| Abbvie INC. | $65.66 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $50.01 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $45.80 | 2025 | Cabometyx |
| Tactile Systems Technology INC | $44.25 | 2023 | Flexitouch Plus, Entre Plus |
| Genentech USA, INC. | $31.91 | 2022-2023 | Venclexta |
| Tempus Ai, INC | $21.87 | 2024 | |
| Servier Pharmaceuticals LLC | $19.02 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $16.24 | 2023 | Libtayo |
| Amgen INC. | $16.17 | 2022 | |
| Pfizer INC. | $12.98 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafiullah Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.